Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a late-stage clinical biopharmaceutical company focused on discovering, developing, and commercializing novel oral antiviral therapies for serious viral diseases. The company leverages proprietary expertise in virology, medicinal chemistry, and antiviral drug development to… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Atea Pharmaceuticals, Inc. does
In the company’s own words
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a late-stage clinical biopharmaceutical company focused on discovering, developing, and commercializing novel oral antiviral therapies for serious viral diseases. The company leverages proprietary expertise in virology, medicinal chemistry, and antiviral drug development to create nucleos(t)ide-based treatments targeting single-stranded RNA viruses.
The company's primary pipeline consists of two lead programs. The first is a combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV) infection, currently in Phase 3 clinical development. This regimen is designed as a protease inhibitor-free, short-duration treatment offering potential advantages over current standard-of-care therapies, including an eight-week treatment course for non-cirrhotic patients and a low risk of drug-drug interactions. The second program is AT-587, an investigational nucleotide analog in preclinical development for treating chronic hepatitis E virus (HEV) infection in immunocompromised patients, with plans to initiate first-in-human Phase 1 studies in mid-2026.
Atea's HCV Phase 3 program includes two randomized trials: C-BEYOND, enrolling over 880 patients in the United States and Canada with topline results expected mid-2026, and C-FORWARD, enrolling approximately 880 patients outside North America with results anticipated at year-end 2026. The company is targeting submission of a New Drug Application to the FDA in March 2027, pending successful Phase 3 outcomes.
The company's competitive positioning rests on its deep scientific expertise in nucleos(t)ide chemistry and antiviral development, combined with a demonstrated track record of efficiently advancing oral direct-acting antivirals through clinical development. The global HCV market represents a substantial opportunity, with branded HCV therapeutics generating over $2.5 billion in net sales in 2025, while the HEV treatment space remains largely unaddressed with no approved direct-acting antivirals currently available.
Atea operates as a smaller reporting company and is not a well-known seasoned issuer. The company's website is www.ateapharma.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1593899
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Atea Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Atea Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Atea Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Atea Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Atea Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”